Clinical Cancer Research

Article	Citations
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies	364
In an Era of ctDNA, Is Metabolomics the New Kid on the Block?	283
Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones	258
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes	232
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases	207
Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice	205
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials	189
Abstract IA-19: Machine learning and AI in molecular pathology diagnostics and clinical management of cancer	187
Interpreting the Complex Landscape of Immune–Tumor Interface	185
Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers	182
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma	178
Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells	172
Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas	159
Challenges to Innovation Arising from Current Companion Diagnostic Regulations and Suggestions for Improvements	155
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial	152
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group	149
Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer	138
Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer	137
Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection	136
Single-Cell Analyses Reveal Mechanisms of Cancer Stem Cell Maintenance and Epithelial–Mesenchymal Transition in Recurrent Bladder Cancer	135
Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities	132
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma	119
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception	118
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia	115
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513	114

Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection	109
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer	106
Abstract PO-056: Importance of artificial intelligence, machine learning deep learning in the field of medicine on the future role of the physician	104
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma	104
TP53 or Not TP53: That Is the Question	103
A Phase II Study of Optimized Individualized Adaptive Radiotherapy for Hepatocellular Carcinoma	101
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma	100
Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges	99
Abstract PO-096: Blocking the CXCL12/CXCR4 pathway both radiosensitizes brain metastases in mice and protects against radiation-induced cognitive dysfunction following whole brain irradiation in rats	96
Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?	96
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models	95
CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade	95
A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer	95
Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting	94
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments	93
Abstract IA-018: Molecular landmarks of tumor hypoxia across cancer types	93
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer	92
Selected Articles from This Issue	90
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer	89
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial	88
Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models	85
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer	80
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group	79
Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years	79
Immunogenomic Landscape of Neuroendocrine Prostate Cancer	79
Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors	79
GATA-3–dependent Gene Transcription is Impaired upon HDAC Inhibition	79
Streamlined Intraoperative Brain Tumor Classification and Molecular Subtyping in Stereotactic Biopsies Using Stimulated Raman Histology and Deep Learning	78
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials	78
Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia	77
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies	76
Selected Articles from This Issue	76
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer	75
Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic ceRNA Network Related to Immune Infiltration in Sarcoma	75
Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation	74
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.	74
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors	74
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer	74
Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets	73
Selected Articles from This Issue	73
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression	73
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma	73
Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma	71
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer	70
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	69
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial	69
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer	68
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)	68
Perioperative ctDNA-Based MRD Detection in NSCLC—Response	68
Selected Articles from This Issue	68

Abstract PO-084: Automated detection of pancreatic ductal adenocarcinoma (PDAC) on CT scans using artificial intelligence (AI): Impact of inclusion of automated pancreas segmentation on the accuracy o	66
Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present	66
Personalized Medicine's Coming of Age: One Drug, One Patient	65
TargetingKRAS-Mutated NSCLC: Novel TKIs and Beyond	65
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet	64
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer	64
Genomic Characterization of de novo Metastatic Breast Cancer	64
Predicting CAR-T cell Immunotherapy Success through ImmunoPET	64
Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers	64
Selected Articles from This Issue	63
Selected Articles from This Issue	63
Abstract PR-007: Targeting FASN improves type I interferon responses in irradiated glioblastoma	63
TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?	62
Selected Articles from This Issue	62
Selected Articles from This Issue	62
Selected Articles from This Issue	62
Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer	62
Selected Articles from This Issue	62
Amplifying the Voice of the Whispering Cancer	61
Taming the Wild-Type Gastrointestinal Stromal Tumor: Improved Tissue Culture	61
Selected Articles from This Issue	61
Selected Articles from This Issue	61
Abstract S09-04: Asymptomatic detection of COVID-19 among cancer patients receiving infusional anti-cancer therapy	60
Abstract IA-010: Deciphering DNA end resection at DSBs	60
Abstract P28: COVID-19 infection and mortality in patients with skin malignancies receiving systemic anti-cancer therapy (SACT): The Guy’s Cancer Centre experience	60
Abstract P29: Pre-COVID-19 pandemic vs. post-COVID-19 pandemic: Sustained participation of minorities in research in a CAP accredited biorepository in UC San Diego, California	59
Abstract P02: Predicting mortality in SARS-CoV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep Neural Network	59
Abstract PO-019: Radiotherapy in cancer is associated with a deletion signature that contributes to poor patient outcomes	59
Abstract IA-024: Sirt2: A tumor suppressor or promotor?	59
Abstract PO-095: Intrinsic and acquired resistance to RIG-I induced anti-tumor responses	59
Abstract P07: Inhibition of androgen-regulated TMPRSS2 and lipogenic enzymes in prostate and lung carcinoma cell lines by a cisplatin prodrug	58
Abstract P22: A high-throughput anti-SARS-CoV-2 IgG testing platform for COVID-19	58
Abstract PO-032: Mechanistic studies of hypoxia as a driver of genomic instability in prostate cancer	58
Abstract P06: Anticancer agent 3-deazauridine has the potential to be effective against COVID-19 due to its inhibition of replication of RNA viruses	58
Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea	58
Abstract P43: Clinical characteristics of COVID-19 infected cancer patients: A retrospective study in Royal Wolverhampton NHS Trust, United Kingdom	58
Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study	57
Abstract IA-003: Oxygen dependent resistance to PARP inhibitors	57
Abstract IA-012: Differential immunological effects of carbon-ion versus photon radiation therapy	57
Abstract PR-006: Pulsed low-dose-rate radiation (PLDR) limits pancreatic pro-tumor stroma aggravation: Pre-clinical basis for an ongoing PLDR trail	57
Abstract PO-018: Hypoxia activated prodrugs of DNA-dependent protein kinase inhibitors as radiosensitisers of head and neck squamous cell carcinomas	56
Abstract P01: Development of a TMB classifier on NSCLC H&E images	56
Abstract PR-005: Adenosine signaling and radiation-induced immunosuppressive changes to the tumor microenvironment	56
Abstract P40: PTSD and levels of general anxiety in Italian oncological patients during the COVID-19 pandemic	56
Abstract IA-021: Predicting radiotherapy outcomes: Radiogenomics and risk of radiotherapy toxicity	56
Abstract P34: Health care disparities and outcomes of cancer patients with COVID-19: A pooled analysis of two Brazilian tertiary centers	56
Abstract P03: Identifying sources of variation in manual segmentation of hippocampus on from magnetic resonance images (MRI)	55
Abstract PO-035: Understanding the role of hypoxia and PTEN loss in driving prostate cancer progression	55
Abstract PO-044: Exploiting a radiotherapy induced immunologic double bind in advanced prostate cancer	55
Abstract PR008: Identifying mechanisms of immune evasion in microsatellite instable endometrial cancer mouse models	54
Abstract PR-008: Identification and characterization of the molecular mechanisms of SCLC chemo-radiation resistance	54
Abstract IA008: Mismatch repair deficiency and survival in stage I endometrial cancer	54
Abstract PO-053: Targeting focal adhesions to limit radiation-induced glioblastoma cell invasion	54
Abstract PO037: Identifying effective combinations of targeted therapies, using novel pre-clinical models, to improve treatment options for high-grade serous endometrial cancer	54
Abstract PO005: A comprehensive analysis of the transcriptional effects of progesterone receptor isoforms A and B identifies VEGF, PDGF and STAT3 as therapeutic targets	54
Abstract PO-097: Selective targeting and imaging of orthotopic glioblastoma after a single systemic dose of a novel hydoxyl dendrimer radionuclide	54
Abstract PO002: Inducing homologous recombination deficiency in uterine serous cancer (USC) using AVB-500, a receptor tyrosine kinase AXL inhibitor	53
Abstract IA005: DNA damaging agents in endometrial cancer	53
Abstract PO029: Oral contraceptive use and postmenopausal sex steroid hormone metabolism	53
Abstract PO013: SNP rs1982 in the 3’UTR of placenta-specific protein 1 (PLAC1) is associated with endometrial cancer survival	53
Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer	53
Abstract IA020: Chromatin regulation of the endometrium: What are our models telling us?	53
Abstract PO015: The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer	53
Abstract IA-26: Artificial intelligence for regulatory science research	52
Abstract IA006: Endocrine therapy and ER/PR combinations	52
Abstract IA015: Molecular stratification: Beyond TCGA	52
Abstract PO-053: Machine learning CADx process for classification of lung nodules below the Lung-RADS 4A threshold in LDCT scans	52
Abstract PR002: Global proteomic profiling of endometrial carcinomas identify prognostic markers	52
Abstract IA-10: Machine learning enabled analysis of high content imaging datasets: Progress and prospects	51
Abstract PR-02: Machine learning models to quantify lineage plasticity and neuroendocrine differentiation in high-grade prostate cancer	51
Abstract PO-089: Morphokinetic single-cell analysis and machine learning as a tool to characterize breast cancer cell motility and response to therapy	51
Abstract PO-027: Associations of radiomics features with tumor necrosis following chemotherapy and/or radiation therapy in patients with extremity soft tissue sarcoma	51
Abstract PO-041: Shape features predicting intrahepatic progression-free and overall survival for SBRT treated HCC patients using radiomics and deep learning based survival models	51
Abstract PO-080: Deep learning-based analysis of heterogeneity of breast cancer cells using lens-free digital in-line holography	50
Abstract PO-090: Application of deep learning methods in predicting survival and identifying high-risk populations from large optum real world breast cancer data	50
Abstract PO-016: Seeing glycolysis on PDAC: Applying deep learning convolutional neural network model	50
Abstract PO-079: Fused LASSO application for gastric cancer image segmentation	50
Abstract PO-059: Recurrence predictive models for patients with hepatocellular carcinoma after radiofrequency ablation based on machine learning algorithms	50
Abstract PR-08: Accurate quantification of tumor DNA in liquid biopsies using deep learning	50
Abstract PO-073: Using machine learning to identify the risk factors of pancreatic cancer from the PLCO dataset	49

Abstract PO-069: A deep learning model assists urine cytology reporting with computational estimates of the nuclear/cytoplasmic ratios of the urothelial cells based on the Paris System	49
Abstract PO-067: AI and CT-radiomics as a tool for breast cancer prognosis and radiomics-gene isolation: Activated MET induced mammary carcinoma as a model	49
Abstract PO-051: Development of web-based quality-assurance tool for radiotherapy target delineation for head and neck cancer: Quality evaluation of nasopharyngeal carcinoma	49
Abstract PO-035: Development of a robust radiomic biomarker of PDL1 expression and patient survival after first-line immunotherapy for non-small cell lung cancer	49
Abstract PO-033: The impact of the variation of CT scanner on the prediction of HPV status in head & neck cancer patients	49
Abstract IA-12: Functional analysis of BRCA regulatory variants with deep learning models	49
Abstract PO-095: The PROState AI Cancer–Decision Support (PROSAIC-DS) pilot study: Clinical decision support technology and its role in prostate cancer MDT meetings	49
Abstract PO-010: Feature pyramid network for revealing tumour infiltrating lymphocyte presence and distribution in a whole slide image	48
Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study	48
Selected Articles from This Issue	48
Abstract PO-001: Deep learning-based image analysis of the histological Glasgow Microenvironment Score in patients with colorectal cancer	48
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer	48
Abstract PO-002: Pan-cancer integrative histology-genomic analysis via interpretable multimodal deep learning	48
Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE	48
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma	48
Abstract S05-02: Plant viral nanoparticle-based adjuvants for cancer immunotherapy and COVID-19 vaccines	48
Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy	47
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study	47
Abstract PO-100: Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy	47
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer	47
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia	47
Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities	46
Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group	46
Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development	46
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis	46
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms	46
Liquid Biopsies for Cancer Genotyping: Coming of Age?	45
Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities	45
Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features	45
Abstract PO040: Chemoprevention and regression of estrogen-induced atypical endometrial hyperplasia by oral SHetA2 in a rat model	45
Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial	45
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma	45
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls	45
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer	45
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma	44
A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1	44
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	44
Selected Articles from This Issue	44
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)	44
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma	44
Identification and Validation of T-cell Receptors TargetingRASHotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy	44
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial	43
Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect	43
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment	43
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials	43
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response—Response	43
Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses	43
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality	43
Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis	43
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer	43
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma	43
Selected Articles from This Issue	42
Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components	42
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00	42
DNMT3A-Mutant Leukemia Cells Primed to “Fork It Over” under DNA Damage	42
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma	42
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors	42
Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception	42
Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women	42
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer	41
Abstract IA-017: Chromatin and gene transcription in hypoxia	41
Clonal Hematopoiesis in Young Women Treated for Breast Cancer	41
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer	41
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer	41
Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets	41
Taking the Road Less Traveled: Following Molecular Trail Markers	41
Abstract PR-12: Towards verifying results from biomedical deep learning models using the UMLS: Cases of primary tumor site classification and cancer Named Entity Recognition	41
A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors	41
Abstract PO-007: Deep learning-based computational pathology predicts origins for cancers of unknown primary	41
Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY)	41
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma	40
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer	40
Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen	40
Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment	40
Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer	40
Consolidating Radiotherapy with Immunotherapy	39
Learning Individual Survival Models from PanCancer Whole Transcriptome Data	39
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4	39
Abstract PO-062: Fully automated artificial intelligence based breast cancer scanning through transilluminated image acquisition for mass screening appliances	39
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy	39
The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity	39
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations	39
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials	39
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma	39
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer	38
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer	38
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis	38
BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance	38
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia	38
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial	38
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types	38
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair	38
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas	38
Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements	38
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer	38